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In brief 
This is the first in a series of five articles describing performance measures developed 
within the ESGE quality improvement committee during the last three years with the 
support of UEG.  The upper GI working group proposes 11 performance measures to 
assess and audit quality of upper gastrointestinal endoscopy. 
 
Introduction 
The European Society of Gastrointestinal Endoscopy (ESGE) and United European 
Gastroenterology (UEG) have identified quality of endoscopy as a major priority and 
we described our rationale for this in a first manuscript that also addressed the 
methodology of the quality initiative process [1].  
The identification of upper gastrointestinal (UGI) performance measures presents a 
considerable challenge, in contrast to the situation with colonoscopy for instance, 
where several performance measures (inspection time, adenoma detection rate, and 
interval cancers, among others) have been identified over the last decade [2,3]. 
Following the Quality in UGI Endoscopy meeting held in Lisbon in 2013, it was clear 
that there was a need to identify performance measures for the UGI tract, and that 
quality standards could be identified although there is a paucity of evidence. This lack 
of evidence helps however to identify research priorities for the development of 
clinical trials that will further validate and substantiate the implementation of 
performance measures. 
The aim therefore of the UGI working group was twofold: (1) to identify performance 
measures for UGI endoscopy; (2) to identify the evidence or absence of evidence that 
would develop the research priorities in this field. 
We used an innovative methodology to facilitate the quality initiative process, which 
combined a thorough search and standardized evaluation of the available evidence for 
each clinical question, followed by a Delphi process 
(http://is.njit.edu/pubs/delphibook/delphibook.pdf. Accessed: July 2016) using an 
online platform [4,5]. This online platform permitted iterative rounds of modification 
and comment by all members of the UGI working group until agreement was reached 
on the performance measure. We now report these newly identified performance 
measures. 
Abbreviations 
CI  confidence interval 
EAC  early adenocarcinoma 
EMR  endoscopic mucosal resection 
ENT  ear, nose, and throat 
ESGE  European Society of Gastrointestinal Endoscopy 
FAP  familial adenomatous polyposis  
GAVE  gastric antral vascular ectasia  
HGD  high grade dysplasia  
LGD  low grade dysplasia 
MAPS  Management of precancerous conditions and lesions in the stomach 
OLGA  Operative Link for Gastritis Assessment 
OLGIM Operative Link on Gastric Intestinal Metaplasia 
OR  odds ratio 
PEG  percutaneous endoscopic gastrostomy 
PICO  population/patient; intervention/indicator; comparator/control; outcome 
PPI  proton pump inhibitor 
QIC  Quality improvement committee 
SCC  squamous cell cancer 
UEG  United European Gastroenterology 
UGI  upper gastrointestinal tract  
Methodology 
We previously described the multistep process for the methodology to develop 
performance measures [1]. Briefly, following the Lisbon meeting in 2013, a list of 56 
possible performance measures was distributed to all of the working group members 
for comments, suggestions, and shortcomings in September 2014. Every participant 
was required to comment on all of the proposed performance measures during 
teleconferences that took place between October 1st and December 18th 2014. 
All possible performance measures that were identified by this process were 
structured using the PICO framework (where P stands for Population/Patient; I for 
Intervention/Indicator; C for Comparator/Control; and O for Outcome) to inform 
searches for available evidence to support the performance measures. This process 
resulted in 67 possible performance measures and 108 PICOs.  
Because of the timeframe for this first initiative and the wide range of pathology in 
the UGI tract, the working group had to prioritize general UGI endoscopy topics 
within the abundance of proposed performance measures and PICOs. As part of this 
prioritization, PICOs that were concerned with areas where guidelines were already 
available or under development were omitted. We also excluded PICOs that focused 
on: the assessment of effectiveness, or comparative effectiveness, of specific 
treatments (e.g. administration of proton pump inhibitors [PPIs] before endoscopy for 
acute bleeding, percentage of patients undergoing endoscopic resection in Barrett’s 
esophagus with high grade dysplasia [HGD] before ablation); legal or local regulation 
(informed consent); histopathology (e.g. the need for confirmation/revision of a 
diagnosis of dysplasia by an independent pathologist); and service working group 
issues (e.g. adequate management of anticoagulants, sedation, etc.).  
The initial priority list was developed during a face-to-face meeting on February 14th 
2015. In total, 44 PICOs were retained as the basis for literature searches. Several 
disease-specific performance measures were also developed (Barrett’s esophagus, 
intestinal metaplasia in the stomach, and squamous cell cancer [SCC] in the 
esophagus).  
The PICOs and the clinical statements derived from these, which were organized into 
eight domains on the basis of their clinical applications, were adapted and/or excluded 
during the iterative rounds of comments and suggestions from the working group 
members during the Delphi process. The evolution and adaptation of the different 
PICOs and clinical statements during the Delphi process can be reviewed in 
Appendix e1 (available online). In total, working group members participated in four 
rounds of voting to agree on the performance measures in predefined domains and 
their respective thresholds, which are discussed below. The agreement that is given 
for the different statements refers to the last voting round in the Delphi process. A 
statement was accepted if at least 80% agreement was reached after a minimum of 
two voting rounds. 
The performance measures are displayed in boxes under the relevant domain. Each 
box describes the performance measure and the rationale behind its adoption, the 
agreement on acceptance during the modified Delphi process, and the grading of the 
available evidence, along with details of how the score should be measured and the 
desired threshold. 
During the Delphi process, the Quality Improvement Committee (QIC) chairs 
distinguished key performance measures from minor performance measures to assist 
service providers with decisions about the implementation of performance measures 
in their endoscopy services. Reasons to qualify a performance measure as minor 
included the measure being very disease specific (e.g. detection of neoplasia during 
surveillance of Barrett’s esophagus or gastric intestinal metaplasia) or that its 
implementation might be relatively difficult and dependent on the availability of 
adequate software for auditing of the performance measures. The division and 
allocation of performance measures to key and minor performance measures was 
agreed by the UGI working group in an additional face-to-face meeting in April 2016. 
The number of cases that need to be audited to adequately assess if the threshold for a 
certain performance measure is reached can be calculated by estimating the 95% 
confidence intervals (CI) for a predefined threshold and variable sample size (see 
Appendix e2, Table e1, available online). For reasons of practicality and feasibility 
when implementing an audit, the working group agreed that 100 procedures (or all, if 
<100 procedures had been performed) should be measured to assess the performance 
measure. Ideally this should be done at an individual procedure level but, as this 
requires robust and sophisticated software, we suggest that the assessment is first 
performed at a service level. If problems are detected at a service level, further 
analysis at an individual level is then required to identify possible targets for 
improvement. 
Performance measures for upper gastrointestinal endoscopy 
In the first round of development, the working group accepted 11 performance 
measures in total, after a total of four voting rounds in the modified Delphi process. 
The evidence quality (assessed using the GRADE criteria [6]) for most of these 
performance measures is low; however, this does not indicate that a performance 
measure is not important.  
Taking into account both the feasibility of implementation and the possible impact on 
diagnostic quality and patient outcome, we identified six key and five minor 
performance measures (Table 2; Fig. 1). Nevertheless, all the performance measures 
were deemed valuable by the working group members and were obtained after a 
rigorous process, as described above. From a practical viewpoint, it may be desirable 
to implement the key performance measures first in those units that are not presently 
monitoring any performance measures. Once a culture of quality measurement is 
accepted and software is available, the minor performance measures may then further 
aid monitoring of the quality of UGI endoscopy. 
All of the performance measures are described below, according to the domain to 
which they are attributed. The PICOs and statements that were used during the 
modified Delphi process to develop the performance measures can be found in 
Appendix e1. The statement numbers correspond to those used in Appendix e1. 
1 Domain: Pre-procedure 
<PerfM> 
Key performance 
measure 
Fasting instructions 
Description Percentage of patients receiving proper instructions for fasting prior to UGI 
endoscopy 
Domain Pre-procedure 
Category Process 
Rationale Patient safety and comfort  
Efficacy of UGI endoscopy 
Construct Denominator: Patients undergoing a UGI endoscopy (note: patients whose 
endoscopies are postponed because of lack of proper instructions should 
also be included in the calculation of the denominator) 
Numerator: Patients in the denominator who received proper instructions for 
fasting (2 hours for liquids and 6 hours for solids), as reported in the pre-
assessment part of the endoscopy report  
Exclusions: Emergency endoscopies 
 
Calculation: Proportion (%) 
Level of analysis: Service level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies on a 
service level 
Standards Minimum standard: 95% 
Target standard: 95% 
 
If the minimum standard is not reached, information channels to patients and 
healthcare providers should be reviewed and revised on a service level 
After evaluation and adjustment, close monitoring should be performed with a 
further audit within 6 months  
Consensus 
agreement for 
performance measure 
91% 
PICO number  
(see Appendix 3) 
1 
Evidence grading Very low quality 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• Patients referred for scheduled UGI endoscopy should be fasting. (Statement number 
N1.1 [see Appendix e1]) Agreement: 100% 
• Patients referred for UGI endoscopy should be fasting for solids for at least 6 hours 
prior to the procedure. (N1.2) Agreement: 91% 
• Patients referred for UGI endoscopy are allowed to take in water until 2 hours prior 
to the procedure. (N1.3) Agreement: 100% 
Two studies were found that addressed these instructions and the duration of fasting 
prior to a scheduled UGI endoscopy [7,8]. In both studies, the authors mainly assessed 
the fasting time for liquids. The fasting time for solids was at least 6 hours prior to the 
endoscopy in both studies, with a good effect on visibility during endoscopy.  
In the study by Koeppe et al. [7], general discomfort was reported less frequently by 
patients who had a drink of water (200 mL) 2 hours before the procedure than in those 
who were fasting for solids and liquids for a full 8 hours (18% vs. 42%; P = 0.010). 
Even though the endoscopists subjectively observed more liquid in the stomach of the 
former group, no cases of aspiration were observed in the sample of 50 lightly sedated 
patients.  
De Silva et al. [8] also reported lower discomfort scores when water ad libitum was 
allowed until 1 hour before the procedure (recorded volumes drunk were 200–
410 mL) compared with no water being allowed during a 6-hour pre-endoscopy fast 
(5.6 vs. 9.7; P < 0.0001). No significant differences were found for complications and 
safety outcomes, apart from a significant difference in the volume of retained fluid in 
the gastric fundus, this being more when water was drunk until 1 hour prior to the 
procedure, which was performed without sedation. Again no cases of aspiration were 
observed.  
The outcome “incomplete examination” was not reported in the retrieved studies. The 
outcome “good or normal visibility of gastric mucosa” could be used as an indirect 
outcome for the evaluation of incomplete examination. This outcome was consistently 
high after both 2 hours/1 hour minimum of no fluids and nil by mouth for at least 
6 hours (96% vs. 98% [7] and 93% vs.100% [8], respectively).  
Although no data from the two available studies directly assessed the duration of 
fasting for solids, it appears that an interval of at least 6 hours is safe and effective for 
UGI endoscopy in patients without any history or predisposing factors for delayed 
gastric emptying. For endoscopies that are planned to be performed in the afternoon, 
patient satisfaction may be increased if a small breakfast is allowed. 
Unlike with colonoscopy, we do not have a standardized scale to measure “gastric 
preparation” for UGI endoscopy. We advise that the contents of the stomach, such as 
food residues, blood, bile, or the presence of bubbles, should be reported, along with 
information on whether a waterjet system was used to improve mucosal visualization. 
Just recording this as a surrogate performance measure may however omit patients 
that are sent home again because they did not receive fasting instructions. Recording 
that proper instructions were given should therefore be done prior to the endoscopy 
itself and this could be included in the pre-assessment part of the endoscopy report 
(together with, for instance, the informed consent). This would mean that patients who 
show up for endoscopy having not received proper instructions and therefore have 
their endoscopy cancelled should be included in any audits of this performance 
measure.  
2 Domain: Completeness of procedure 
<PerfM> 
Key performance 
measure 
Documentation of procedure duration 
Description Percentage of endoscopy reports that record the duration of the procedure 
from intubation to extubation 
Domain Completeness of procedure 
Category Process 
Rationale Completeness of UGI endoscopy cannot be defined only by the duodenum 
having been reached  
A longer inspection time reflects a more complete examination and is related 
to higher diagnostic yield during UGI endoscopy 
Construct Record the time from intubation to extubation of the endoscope 
 
Denominator: All UGI endoscopies 
Numerator: Procedures in the denominator that report the time of the 
procedure from intubation to extubation   
Exclusions: None 
 
Calculation: Proportion (%) 
Level of analysis: Service and, if necessary, individual level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies. If the 
minimum standard is not reached, analysis on an individual level should be 
performed 
Standards Minimum standard: 90% 
Target standard: 90% 
 
Recording the duration of an examination should be attempted and should 
mostly be possible 
If the threshold is not reached on a service level, the service should assess 
whether technical support is sufficient to accurately record the procedure time 
If the threshold is not reached for an individual endoscopist, feedback should 
be provided, followed by close monitoring for 3 months to assess the 
performance of the individual endoscopist 
After evaluation and adjustment, close monitoring should be performed with a 
further audit within 6 months  
Consensus 
agreement for 
performance measure 
82% 
PICO numbers 
(see Appendix 3) 
2,3 
Evidence grading Very low quality 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• A UGI endoscopy in a patient who has not undergone a previous gastroscopy within 
the last 3 years should include inspection of the esophagus, stomach, and duodenum, 
and should last for at least 7 minutes from intubation to extubation. (N2.2) 
Agreement: 80% 
• Although the evidence to support this is of very low quality, the major duodenal 
papilla should be visualized and photographed in all UGI endoscopies in patients with 
normal anatomy when a full examination is intended. (N2.1) Agreement: 73% 
In contrast to colonoscopy, there is a paucity of data on the assessment of a complete 
procedure. As a definition, “reaching the duodenum” seems too trivial: it does not 
really reflect endoscopic competence as it is easy to achieve; there is no data 
comparable to cecal intubation rate in the colon that supports its relationship to better 
disease detection.  
During the discussions of the working group, there was a strong emphasis on trying to 
define this performance measure and searching the literature for an anatomical 
landmark or finding that might be related to disease detection. We formulated several 
PICOs to assess whether reaching any specific anatomical landmark yielded a better 
rate of diagnosis. One may speculate whether documentation that the major papilla 
has been visualized can serve as an auditable performance measure for completeness 
of the procedure in a patient referred for a complete UGI endoscopy. Analogous to 
cecal intubation, it cannot be achieved in all endoscopies and is less trivial than 
reaching the second portion of the duodenum. In the absence however of any data to 
support this, no consensus was reached on this statement (only 73% agreement) and 
the working group therefore formulated this as one of the research priorities 
(Table 3).  
We did however find one study that aimed to evaluate whether the length of time 
spent on UGI endoscopy improved the diagnostic yield. This was a retrospective 
cohort study by Teh et al. [9] that aimed to determine the diagnostic yield for early 
neoplastic lesions in the stomach. The study included 837 symptomatic patients with 
no history of gastric cancer who underwent a first diagnostic endoscopy by one of 16 
endoscopists. The mean examination time for the 224 examinations without any 
abnormal findings or biopsies taken was 6.6 minutes, which allowed the definition of 
a cut-off time of ≥7 minutes to distinguish between “slow” versus “fast” procedures. 
Afterwards, in a retrospective evaluation of the 837 endoscopies, they concluded that 
a “slow” endoscopist (who took on average at least 7 minutes to perform a normal 
endoscopy) was twice as likely to detect high risk gastric lesions, defined as biopsy 
evidence of intestinal metaplasia, gastric atrophy, gastric dysplasia, or cancer (odds 
ratio [OR] 2.50, 95%CI 1.52–4.12) and three times as likely to detect a case of 
dysplasia or cancer (OR 3.42, 95%CI 1.25–10.38) than a “fast” endoscopist (who took 
fewer than 7 minutes on average).  
A similar concept of measuring length of time for inspection, but in the specific 
context of Barrett’s esophagus, has shown increased detection of dysplasia with an 
inspection time of 1 minute per cm of Barrett’s esophagus [10].  
 Only one study has evaluated the correlation between increased detection of gastric 
dysplasia or gastric cancer and other UGI endoscopic diagnoses [11]. Park et al. 
retrospectively analyzed 54 889 records of patients who underwent a screening UGI 
endoscopy, performed by 66 experienced endoscopists, from 2006 to 2013 in a single 
center in Korea. Any diagnoses of reflux esophagitis, Barrett’s esophagus, atrophic 
gastritis, intestinal metaplasia, erosion, ulceration, polyps, subepithelial lesions, 
xanthoma, angiodysplasia, or a diverticulum were recorded and the relevant records 
were re-evaluated with respect to increased detection of early gastric neoplasia. In 
multivariate analysis, the detection rates of gastric subepithelial lesions and gastric 
diverticula were independently associated with the detection rate of early gastric 
neoplasms. 
<PerfM> 
Key performance 
measure 
Accurate photodocumentation 
Description Percentage of endoscopy reports with accurate photodocumentation of 
anatomical landmarks and all abnormal findings 
Domain Completeness of procedure 
Category Process 
Rationale Photodocumentation of all anatomical landmarks is an indicator of a complete 
examination 
Accurate photodocumentation of abnormal findings allows for better 
communication and follow-up 
Construct Accurate photodocumentation includes at least one representative picture of 
each of the following anatomical landmarks: duodenum, major papilla, 
antrum, angulus, corpus, retroflex of the fundus, diaphragmatic indentation, 
upper end of the gastric folds, squamocolumnar junction, distal and proximal 
esophagus (i.e. at least 10 images in total)  
There should be pictures of all abnormal findings mentioned in the report 
 
Denominator: All diagnostic UGI endoscopies 
Numerator: Procedures in the denominator that contain accurate 
photodocumentation, as detailed above 
Exclusions: 
– Therapeutic procedures 
– Follow-up endoscopies performed within 12 months of a previous 
endoscopy and for a previously diagnosed disease or condition (coeliac 
disease, varices, ulcers, cancer after any treatment, dysplastic Barrett’s 
esophagus, gastric dysplasia, duodenal polyps, infections, inflammation, 
bleeding, or endoscopic treatment of any of the aforementioned) 
– Emergency endoscopy 
– Endoscopy with a specific diagnostic purpose without the need for a full 
evaluation: evaluation of a fistula or perforation 
– Early termination of endoscopy due to patient intolerance or for reasons of 
safety 
 
Calculation: Proportion (%) 
Level of analysis: Service and, if necessary, individual level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies. If the 
minimum standard is not reached, analysis on an individual level should be 
performed 
Standards Minimum standard: 90% 
Target standard: 90% 
 
If the threshold is not reached on a service level, the service should assess 
whether technical support is sufficient for image acquisition and integration 
into the report 
If the threshold is not reached for an individual endoscopist, feedback should 
be provided, followed by close monitoring for 3 months to assess the 
performance of the individual endoscopist 
After evaluation and adjustment, close monitoring should be performed with a 
further audit within 6 months 
Factors such as whether the examination is diagnostic or therapeutic should 
be recorded to allow subgroup analysis and future adaptation of the 
performance measure 
Consensus 
agreement for 
performance measure 
91% 
PICO numbers 
(see Appendix 3) 
4,5 
Evidence grading Very low quality 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• High quality reporting includes photodocumentation of all normal anatomical 
landmarks and abnormal findings. (N3.1) Agreement: 100% 
• An accurate endoscopy report for reflux disease includes documentation of the 
anatomical hallmarks (diaphragm indentation, top of gastric folds). (N4.1) 
Agreement: 100% 
• An accurate endoscopy report for reflux disease includes application of the Los 
Angeles classification. (N4.2) Agreement: 100% 
• An accurate endoscopy report for Barrett’s esophagus includes documentation of the 
anatomical landmarks (diaphragm indentation, top of gastric folds). (N4.3) 
Agreement: 100% 
• The Prague criteria should be used to report the results of endoscopic examination of 
Barrett’s esophagus. (N4.4) Agreement: 100% 
No data exist to support that photodocumentation of all normal anatomical landmarks 
and abnormal findings will improve diagnostic yield. However, photodocumentation 
should be considered a general quality improvement in comparison with previous 
reports that were made before dedicated reporting software was available. Most 
endoscopic systems now enable digital picture acquisition, therefore the working 
group strongly agreed on the inclusion of digital photography in reports. This measure 
is supported by endoscopic societies and experts suggest it might be an indirect 
quality indicator for careful inspection of the digestive lumen [12–14].  
The minimum number of pictures to be collected, combining relevance and 
applicability, in a normal endoscopic examination should be 10, namely: proximal 
esophagus, distal esophagus, Z line and diaphragm indentation, cardia and fundus in 
inversion, corpus in forward view including lesser curvature, corpus in retroflex view 
including greater curvature, angulus in partial inversion, antrum, duodenal bulb, and 
second part of duodenum. The working group suggested that it may be desirable to 
document more extensively in specific surveillance examinations, such as for 
Barrett’s esophagus (e.g. one picture per cm of Barrett’s esophagus) [10], or where 
there are extensive gastric premalignant conditions (e.g. 21 pictures of the 
stomach) [13]. 
In addition, several validated classifications have been developed for specific 
pathologies. The working group agreed that the use of these classifications in 
conjunction with photodocumentation improves comparability and accurate 
information exchange among gastroenterologists, both in the clinical setting and for 
investigational purposes. In the UGI tract, this is especially true for the Los Angeles 
classification for the reporting of reflux esophagitis and the Prague classification for 
Barrett’s esophagus [15–18]. 
Implementation of this performance measure is inevitably dependent on the 
availability of image acquisition and software to incorporate images into the report. 
Because this performance measure simplifies and improves communication between 
different endoscopists, implementation of appropriate software should be prioritized 
by hospital policy makers. The working group recognizes that gastroenterologists 
performing procedures mainly in their own surgeries will often struggle to find a 
reasonable way to be reimbursed for the considerable cost of this software. 
3 Domain: Identification of pathology 
<PerfM> 
Minor performance 
measure 
Inspection time in the stomach 
Description Percentage of first-time gastroscopies and follow-up gastroscopies for gastric 
intestinal metaplasia lasting more than 7 minutes from intubation to 
extubation 
Domain Identification of pathology 
Category Process 
Rationale Longer inspection times allow the detection of more lesions in the stomach 
Construct Record time from intubation to extubation of the endoscope 
 
Denominator: First-time diagnostic UGI endoscopies or follow-up 
gastroscopies for gastric intestinal metaplasia 
Numerator: Procedures in the denominator with the duration of the 
procedure documented as being at least 7 minutes from intubation to 
extubation (note: procedures without a recorded time should be regarded as 
fails) 
Exclusions: 
– Therapeutic procedures 
– Follow-up endoscopy within 36 months of a previous endoscopy for follow-
up of gastric intestinal metaplasia 
– Emergency endoscopy 
– Endoscopy with a very specific diagnostic focus where there is no intent to 
detect stomach pathology: e.g. evaluation of a fistula, perforation 
– Early termination of endoscopy due to patient intolerance or for reasons of 
safety 
 
Calculation: Proportion (%) 
Level of analysis: Service and, if necessary, individual level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies. If the 
minimum standard is not reached, analysis on an individual level should be 
performed 
Standards Minimum standard: 90% 
Target standard: 90% 
 
Recording the duration of an examination should be attempted and should 
mostly be possible 
If the threshold is not reached on a service level, the service should assess 
whether technical support is sufficient to accurately record the procedure time 
If the threshold is not reached for an individual endoscopist, feedback should 
be provided, followed by close monitoring for 3 months to assess the 
performance of the individual endoscopist 
After evaluation and adjustment, close monitoring should be performed with a 
further audit within 6 months  
Consensus 
agreement for 
performance measure  
82% 
PICO number 
(see Appendix 3) 
1 
Evidence grading Very low quality evidence 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• The entire procedure for surveillance of intestinal metaplasia should last at least 
7 minutes from scope intubation to scope extubation of the patient (N6.1). Agreement: 
100% 
• A UGI endoscopy in a patient who has not undergone a previous gastroscopy within 
the last 3 years should include inspection of the esophagus, stomach, and duodenum, 
and should last for at least 7 minutes from intubation to extubation. (N2.2) 
Agreement: 80% 
The evidence for this performance measure is mainly derived from the study by Teh 
et al. [8]. By using a cut-off time of ≥7 minutes per endoscopy, from intubation to 
extubation, endoscopists performing above the cut-off (i.e. longer inspection times) 
detect two times as many high risk gastric lesions (intestinal metaplasia, gastric 
atrophy, gastric dysplasia, or cancer) and three times as many dysplastic lesions and 
gastric cancers. The study did not evaluate differing diagnostic yields in the 
esophagus or duodenum between endoscopists but it provides evidence for the 
stomach that is comparable to that for inspection times in the colon [18]. 
The interval of 3 years in the statement from the Delphi process stems from the 
suggestion of the European consensus on “Management of precancerous conditions 
and lesions in the stomach” (MAPS guideline) [19,20]. The 3-year interval was 
suggested among experts to be the best clinically applicable interval for endoscopic 
surveillance of extensive atrophy and/or extensive intestinal metaplasia. This 3-year 
interval strategy has been shown more recently, in a European population between 50 
and 75 years of age, to be cost-effective as a surveillance strategy [21]. 
<PerfM> 
Key performance Use of standardized terminology 
measure 
Description Percentage of endoscopy reports with accurate application of standardized 
disease-related terminology 
Domain Identification of pathology 
Category Process 
Rationale Uniformity in communication 
Construct Record the use of the:  
– Los Angeles classification for erosive esophagitis 
– Zargar classification for caustic esophagitis 
– Prague classification for Barrett’s esophagus 
– Forrest classification for bleeding ulcers 
– Spigelman classification for duodenal adenomas in patients with familial 
adenomatous polyposis (FAP) 
– Paris classification for visible lesions in the stomach and esophagus 
– Baveno classification for varices 
 
Denominator: All endoscopy reports addressing one or more of the 
aforementioned group of pathologies 
Numerator: Reports with appropriate use of all disease-related terminology 
The performance measure is only met when all applicable disease-related 
terminology is used in a report, so for instance in a patient with esophagitis 
and Barrett’s esophagus both the Los Angeles and Prague classifications 
should be used 
Exclusions: None, but limited to the specified diseases 
 
Calculation: Proportion (%) 
Level of analysis: Service and, if necessary, individual level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies. If the 
minimum standard is not reached, analysis on an individual level should be 
performed 
Standards Minimum standard: 95% 
Target standard: 95% 
 Recording of the final diagnosis of the endoscopy is fundamental to allow the 
calculation of this performance measure and therefore its implementation 
may be more difficult 
If the threshold is not reached at a service level, the service should assess 
whether technical support is sufficient to make a search for auditable 
endoscopies feasible, based on software that allows the diagnosis on an 
endoscopy report to be searched 
If the threshold is not reached for an individual endoscopist, feedback should 
be provided, followed by close monitoring for 6 months to assess the 
performance of the individual endoscopist 
After evaluation and adjustment, close monitoring should be performed with a 
further audit within 6 months 
Consensus 
agreement for 
performance measure 
91% 
PICO numbers 
(see Appendix 3) 
6–13 
Evidence grading Very low quality 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• Abnormal findings should be reported according to available internationally 
validated and standardized terminology. (N3.2) Agreement: 100% 
• An accurate endoscopy report for reflux disease includes application or the Los 
Angeles classification. (N4.2) Agreement: 100% 
• The Prague criteria should be used to report the results of endoscopic examination of 
Barrett’s esophagus. (N4.4) Agreement: 100% 
The quality of endoscopy is closely related to the quality of the report and the use of 
standardized terminology enables better communication between endoscopists and 
unequivocal discrimination of disease-related findings.  
The working group considered accurate reporting as one of the main topics for quality 
assurance. Besides reporting and documentation of anatomical landmarks, the correct 
use of available and validated terminology for specific diseases was considered to be a 
cardinal point for quality improvement. It enables the gathering of sound 
epidemiological data and is a prerequisite for auditing the quality of endoscopic 
reports. Although the literature searches for the PICOs did not render any evidence in 
terms of higher diagnostic yield or proven efficacy for better physician interaction and 
communication, the statements on implementing standardized terminology as a 
quality measure for accurate reporting all reached 100% agreement.  
The Paris classification is a uniform and relatively well established endoscopic 
classification for early neoplastic lesions [22,23], with clinical value in terms of the 
prediction of the risk of submucosal invasion and therefore eligibility for endoscopic 
treatment [23]; however, little is known about the interobserver agreement of this 
classification. Recently, the value of this classification system has been questioned in 
an interobserver study for polyp assessment in the colon, which showed a Kappa 
value of 0.42 and a mean pairwise agreement of 67% [24]. This study indicates that 
further research is clearly necessary to assess the applicability of the Paris 
classification or perhaps to simplify it.  
The Los Angeles classification for erosive reflux disease was validated when it was 
introduced in 1996 [25] and demonstrated that interobserver agreement for the 
assessment of minimal changes, mucosal breaks, demarcated areas of slough or 
erythema, and complications was good. Because of the availability of interobserver 
data and the fact that this classification is now used most widely, the working group 
opted to implement the Los Angeles classification as the standard for endoscopic 
assessment of reflux disease [25,26].  
Similarly, the Prague classification is a relatively straightforward and reproducible 
score, which enables better communication between endoscopists. The score has been 
validated among experts [18] and in two additional studies among trainees and 
community-based endoscopists, strengthening the value of the Prague classification 
for the accurate description of Barrett’s esophagus and the length of the hiatal 
hernia [27,28].  
The ESGE guideline on the diagnosis and management of nonvariceal UGI bleeding 
has strongly recommended the uniform use of the Forrest classification, as used in 
several studies assessing the risk for peptic ulcer bleeding and rebleeding [29,30]. 
Therefore it is clinically important that this classification is used in the endoscopy 
report in order to ascertain the correct clinical management after endoscopy for UGI 
bleeds [31].  
Other classification systems that should be implemented are the Zargar’s 
classification for caustic esophagitis [32], the Baveno classification for grading of 
esophageal varices [33,34], and the Spigelman’s classification for duodenal polyps in 
FAP syndrome [35,36]. Although there is less data available in terms of 
reproducibility, these scoring systems are relatively simple to apply and have an 
intrinsic clinical value in terms of patient management and follow-up. 
The working group accepted that although agreement was reached about the use of the 
aforementioned standardized terminology in the modified Delphi process, its 
implementation may be not so easy. In particular, in order to provide data that will 
enable this performance measure to be audited, there is a requirement for an adequate 
electronic reporting system that can match a diagnosis (e.g. bleeding duodenal ulcer) 
to the standardized terminology being used (Forrest classification). A prerequisite of 
such a reporting system is that it would permit automated queries to be run at regular 
intervals and feedback to be supplied to individual endoscopists. Outputs from such 
reporting systems can help to improve the performance for this measure: for instance, 
the system can be adapted to provide a reminder of the criteria of the relevant 
classification system and so that a report cannot be validated unless, when a particular 
diagnosis has been made, the corresponding terminology is used. If such a system is 
in place, systematic electronic reports are encouraged and the over-riding of this 
requirement by the endoscopist should be discouraged.   
<PerfM> 
Minor performance 
measure 
Inspection time of Barrett’s esophagus 
Description Percentage of routine Barrett’s surveillance endoscopies with at least 
1 minute of inspection time per cm of circumferential Barrett’s epithelium 
Domain Identification of pathology 
Category Process 
Rationale Better detection of Barrett’s neoplasia 
Construct Record inspection time of the esophagus 
Record the Prague classification 
Calculate the inspection time expressed as minutes/circumferential extent of 
Barrett’s epithelium in cm 
 
Denominator: Barrett’s surveillance endoscopies 
Numerator: Procedures in the denominator with an inspection time of 
>1 minute per cm of circumferential Barrett’s epithelium 
Exclusions: 
– Presence of severe esophagitis defined as a Los Angeles classification of 
grade C or higher 
– Therapeutic procedures for treatment of Barrett’s esophagus 
 
Calculation: Proportion (%) 
Level of analysis: Service and, if necessary, individual level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies. If the 
minimum standard is not reached, analysis on an individual level should be 
performed 
Standards Minimum standard: 90% 
Target standard: 90% 
 
Recording of the diagnosis of an examination (Barrett’s esophagus) and the 
extent of the Barrett’s epithelium (Prague classification) are fundamental to 
allow the calculation of this performance measure. On a service level this is a 
prerequisite that, if not possible, may hamper implementation in the short 
term 
If on a service level this performance measure is not met, measures should 
be taken to implement software that will allow the performance measure to be 
audited 
If the threshold is not reached for an individual endoscopist, feedback should 
be provided, followed by close monitoring for the next 30 procedures or a 
period of 6 months to assess the performance of the individual endoscopist 
Consensus 
agreement for 
performance measure 
91% 
PICO number  
(see Appendix 3) 
14 
Evidence grading Very low quality evidence 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statement: 
• Inspection time in the esophagus for surveillance of a Barrett’s segment should be at 
least 1 minute/cm of circumferential extent of Barrett’s epithelium. (N4.5) 
Agreement: 90% 
No studies were found that have directly addressed the comparison between 
measuring or not measuring the inspection time. One study aiming to determine 
whether the inspection time in Barrett’s esophagus correlated with the detection of 
endoscopically suspicious lesions and/or Barrett’s esophagus-associated neoplasia, 
namely HGD or early adenocarcinoma (EAC), was considered partially relevant [10]. 
It was a cross-sectional post hoc analysis of data from a multicenter, prospective 
clinical trial of 112 patients that investigated the performance of novel imaging 
techniques for dysplasia detection during Barrett’s esophagus surveillance. The study 
found that greater proportions of patients had an endoscopically suspicious lesion with 
increasing inspection times (≤2 minutes, 30%; 3–4 minutes, 35.5%; 5–6 minutes, 
82.1%; ≥7 minutes, 84.6%; P < 0.001) and a greater proportion were found to have 
HGD/EAC (≤2 minutes, 15%; 3–4 minutes, 32.3%; 5–6 minutes, 46.4%; ≥7 minutes, 
69.2%; P = 0.001). The study suggested that an inspection time of 1 minute per cm of 
Barrett’s esophagus resulted in increased detection of neoplasia. 
Although this study had certain limitations and did not reflect the real-life prevalence 
of Barrett’s esophagus dysplasia in a community-based hospital, the working group 
members agreed to support this performance measure with a high degree of 
agreement. In contrast to the detection of colon polyps, where a solid scientific basis 
seems to exist with regard to the measurement of inspection time during withdrawal 
[3,19] as a performance measure, for UGI endoscopy there is a paucity of scientific 
data [9,10]. Nonetheless, it seems reasonable to assume that a lengthier inspection of 
Barrett’s esophagus may result in better lesion detection.  
The optimal inspection time also includes rinsing the esophagus sufficiently to 
improve visualization, proper sedation and patient tolerance, and the use of high 
definition endoscopy (i.e. high definition endoscopes connected to high definition 
monitors using a high definition signal). At this time, there are no data to support the 
systematic use of any advanced imaging technique, such as chromoendoscopy or 
electronically enhanced endoscopy [37,38], but neither is there harm in applying them 
when available. In the recent BOB CAT consensus, it was suggested that these 
techniques should be used in experienced hands only [4].  
The implementation of this performance measure is again dependent on the 
availability and development of an electronic reporting system; however, once this is 
in place, it should be easy to comply with. One of the research priorities should be to 
elucidate whether there is a correlation between inspection time and increased 
neoplasia detection in Barrett’s esophagus in a general secondary-care setting. 
<PerfM> 
Minor performance 
measure 
Use of Lugol chromoendoscopy in patients with an increased risk of 
SCC 
Description Percentage of procedures with accurate application of chromoendoscopy in 
patients referred for screening for SCC after curative treatment of ear, nose, 
and throat (ENT) or lung cancers 
Domain Identification of pathology 
Category Process 
Rationale Better detection of early esophageal SCC in patients with an increased risk 
Construct Record the use of Lugol chromoendoscopy in patients with a history of ENT 
or lung cancer treated with a curative intent  
 
Denominator: All endoscopies performed for screening for a second primary 
tumor after curative treatment of ENT or lung cancer 
Numerator: Procedures in the denominator where Lugol chromoendoscopy 
is used  
Exclusions: 
– Allergy to iodine 
– Patients treated without curative intent 
– Patients older than 80 years 
– Patients with a life expectancy of less than 2 years 
 
Calculation: Proportion (%) 
Level of analysis: Service  
Frequency: Every 2 years for a sample of all or 100 eligible UGI endoscopies, 
whichever is the larger 
Standards Minimum standard: 90% 
Target standard: 90% 
 
Because this is a relatively rare indication that may be disseminated among 
the endoscopists within a service, as a first step, feedback on a service can 
be provided. If the threshold is not met, endoscopists need to be educated 
about the risk in these patients and the additional value of Lugol staining for 
the detection of early lesions  
Consensus 
agreement for 
performance measure 
82% 
PICO number 
(see Appendix 3) 
15 
Evidence grading Moderate quality 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statement: 
• Accurate use of chromoendoscopy in patients with a history of ENT or lung tumors 
who are treated with curative intent results in a higher diagnostic yield for the 
detection of squamous dysplasia and SCC (N5.1). Agreement: 80% 
Eight studies addressed this clinical question specifically in patients with a history of 
head and neck tumors by comparing conventional white-light endoscopy with Lugol 
chromoendoscopy [39–46]. Because this is a screening examination by a minimally 
invasive technique, from a clinical point of view it only makes sense to perform it in 
patients who have been previously treated with curative intent for their primary tumor. 
For the diagnosis of SCC, five of the studies showed improvements in the rates of 
diagnosis, mostly for early cancers, ranging from 20% to 100% of detected lesions 
[39,41,42,45,46], while all eight studies showed increased yield for dysplasia ranging 
from 33% to 100% of lesions. The overall incidence rates of lesions in this particular 
high risk group of patients were 2%–9% for dysplasia and 1%–5% for cancer after 
Lugol chromoendoscopy.  
The usual technique in UGI endoscopy uses esophageal staining with 10–20 mL of a 
2% Lugol dye solution applied by a spray catheter or directly by the biopsy channel of 
the endoscope, with the esophageal examination being repeated 2 minutes later. In 
view of the fact that Lugol chromoendoscopy is a cheap and relatively easily applied 
technique, for which the available evidence is of moderate quality, the working group 
reached a high degree of agreement on the acceptance of this performance measure. 
4 Domain: Management of pathology 
<PerfM> 
Key performance 
measure 
Use of the Seattle protocol in Barrett’s surveillance 
Description Percentage of patients undergoing routine Barrett’s surveillance with proper 
application of the Seattle protocol 
Domain Management of pathology 
Category Process 
Rationale Accurate surveillance with optimal detection of Barrett’s neoplasia  
Allowing an interval between surveillance endoscopies that is according to 
the guidelines 
Construct Record the Prague classification 
Record the use of the Seattle protocol with four biopsies taken every 2 cm 
along the circumferential extent of the Barrett’s epithelium. Biopsies should 
be collected in separate jars for targeted biopsies and per level for random 
biopsies 
For example, in a C4M5 Barrett’s segment, at least 12 biopsies should be 
taken, i.e. four at levels 0, 2, and 4 cm, and these should be put into three 
different jars numbered according to the biopsy location 
 
Denominator: All Barrett’s surveillance endoscopies 
Numerator: Procedures in the denominator where biopsies were taken in 
complete accordance with the extensive Seattle protocol, as described above 
Exclusions: 
– Presence of severe esophagitis defined as Los Angeles classification of 
grade C or higher 
– Therapeutic procedures for treatment of Barrett’s esophagus 
– Work-up endoscopy for known Barrett’s neoplasia when a visible lesion is 
present that is defined as a type IIa, IIc, Is, or a more advanced lesion 
according to the Paris classification 
– Patients with contraindications for biopsies, such as coagulopathy or the 
use of anticoagulants 
 
Calculation: Proportion (%) 
Level of analysis: Service and, if necessary, individual level 
Frequency: Yearly for a sample of 100 consecutive UGI endoscopies. If the 
minimum standard is not reached, analysis on an individual level should be 
performed 
Standards Minimum standard: 90% 
Target standard: 90% 
 
Recording of the diagnosis of Barrett’s esophagus and the Prague 
classification are fundamental to allow the calculation of this performance 
measure. In addition, a link with a pathology database would be ideal to allow 
automatic audit 
If the threshold is not reached on a service level, the availability of registration 
of the parameters should first be facilitated; if this is available, awareness of 
the need for registration should be increased 
If the threshold is not reached for an individual endoscopist, feedback should 
be provided, followed by a close monitoring for the next 30 procedures or a 
period of 6 months to assess the performance of the individual endoscopist 
Consensus 
agreement for 
performance measure 
100% 
PICO numbers 
(see Appendix 3) 
16–18 
Evidence grading Very low quality of evidence 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statement: 
• In patients undergoing routine surveillance for non-dysplastic Barrett’s esophagus, 
biopsies should be taken according to the Seattle protocol. (N4.6) Agreement: 100% 
The Seattle protocol typically consists of targeted biopsies of any visible lesion, 
followed by four quadrant biopsies taken every 2 cm along the extent of the 
circumference of the Barrett’s esophagus [47], all collected in different containers per 
level and per lesion. This is generally accepted in guidelines to be the standard 
method for Barrett’s esophagus surveillance [37,38,48].  
The acceptance of this protocol dates back to several observational – sometimes 
contradictory – studies, which were mainly performed in an era prior to advanced 
imaging, that suggested better detection of neoplasia and possibly a reduction in 
mortality. In a retrospective cohort study including 362 patients with ≥3 cm Barrett’s 
esophagus undergoing endoscopic surveillance, 180 patients received a systematic 
Seattle biopsy protocol and 182 subjects received a non-systematic biopsy strategy 
[49]. The Seattle protocol detected significantly more low grade dysplasia (LGD; 
18.9% vs. 1.6%; P < 0.001) and HGD (2.8% vs. 0%; P = 0.03). In the non-Seattle 
biopsy group, three patients died of invasive Barrett’s esophagus adenocarcinoma, 
compared with none in the Seattle group. In concordance with this study, Peters et al. 
[50] reported a cohort of patients treated endoscopically for early Barrett’s esophagus 
neoplasia and found that those without a prior diagnosis of dysplasia were more likely 
not to have undergone the Seattle biopsy protocol.  
In the era prior to an established endoscopic treatment of early Barrett’s esophagus 
neoplasia particularly, controversy existed as to whether an intensified protocol better 
predicted the presence of cancer in comparison to a less intensive protocol. Reid et al. 
[47] intensified the classical protocol to four quadrant biopsies every 1 cm for patients 
followed up after a diagnosis of HGD and suggested that a 2-cm biopsy protocol 
would miss 50% of the cancers. In contrast, Kariv et al. [51] found that a 2-cm 
interval for the biopsy protocol was sufficient to detect cancer prior to 
esophagectomy. Studies using advanced imaging techniques in experienced referral 
centers suggest that in the future there may be a role for new techniques to replace the 
Seattle protocol, but currently there are insufficient data to support this [38].  
Because of the widespread acceptance of this protocol in all guidelines, the working 
group agreed fully that, despite the low quality evidence, adherence to the Seattle 
protocol could serve as a valuable performance measure to monitor UGI endoscopy 
practice. It is important to emphasize that this parameter is only applicable in the 
surveillance setting.  
From a practical viewpoint, containers should be labelled according to the level at 
which the biopsy was taken. The working group suggests a coding system that 
unequivocally allows a location to be allocated to each container using a two number 
combination “xxyy.” In this “xx” refers to the distance from the incisors and “yy” to 
the location on a clock with the 3 o’clock position corresponding to the lesser 
curvature (scope in neutral position) and with 00 indicating random biopsies. For 
instance, 4000 would indicate random biopsies taken at 40 cm from the incisors, while 
3805 stands for a targeted biopsy taken from a lesion at 38 cm from the incisors and in 
the 5 o’clock position.  
<PerfM> 
Minor performance 
measure 
Identification of patients at risk for gastric cancer 
Description Percentage of patients in which MAPS guidelines are followed when 
applicable 
Domain Management of pathology 
Category Process 
Rationale Accurate application of the MAPS guidelines identifies patients at risk for 
gastric cancer 
Adequate surveillance allows the detection of gastric cancer at an early stage 
Construct Record the procedures in which gastritis is detected, and where screening for 
HP gastritis and intestinal metaplasia are performed 
Record if at least two biopsies from the antrum and two biopsies from the 
corpus were taken and placed into two different jars for histology (MAPS 
guidelines) 
 
Denominator: All endoscopic examinations where assessment of the gastric 
cancer risk is considered clinically relevant (see exclusion criteria)  
Numerator: Procedures in the denominator in which at least two biopsies 
from the antrum and two biopsies from the corpus were taken and placed into 
two different jars 
Exclusions: 
– Therapeutic procedures 
– UGI with normal gastric findings 
– Gastric findings that do not need the application of guidelines 
– Follow-up of intestinal metaplasia 
– Work-up endoscopy for known gastric dysplasia 
 
Calculation: Proportion (%) 
Level of analysis: Service 
Frequency: Every 2 years for a sample of 100 eligible UGI endoscopies 
Standards Minimum standard: 90% 
Target standard: 90% 
 
Recording the diagnosis of an examination is fundamental to allow further 
assessment of the gastric cancer risk and calculation of this performance 
measure. Implementation may therefore be difficult and depend largely on the 
availability of applicable software on a service level 
If the threshold is not reached on a service level, the availability of registration 
for the parameters should be facilitated. If this is in place, awareness of the 
need to follow the MAPS guidelines should be raised 
Consensus 
agreement for 
performance measure 
91% 
PICO number 
(see Appendix 3) 
19 
Evidence grading Very low quality of evidence 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• For the diagnosis of intestinal metaplasia and Helicobacter pylori, at least two 
biopsies of the antrum and two biopsies of the corpus should be taken. (N6.2) 
Agreement: 80% 
• In addition to two biopsies of the antrum and two biopsies of the corpus, a biopsy in 
the incisura is demanded for both the Operative Link for Gastritis Assessment 
(OLGA) and Operative Link on Gastric Intestinal Metaplasia (OLGIM) 
classifications. (N6.3) Agreement: 80% 
The MAPS guideline recommends that for the assessment of extension of gastric 
atrophy and intestinal metaplasia, beyond performing the best available endoscopy in 
terms of technology and the time for inspection, at least two biopsies must be taken 
from the antrum and two from the body of the stomach, and these must be placed into 
separate containers [20]. This recommendation is in concordance with the minimum 
standards for pathology as described in the OLGA or OLGIM grading systems for 
gastritis [52,53]. These grading systems require an additional separate biopsy from the 
incisura. However, several studies have addressed the issue of the number of biopsies 
and inconsistency exists regarding the incisura biopsy in terms of increased diagnostic 
yield [54–59]. 
De Vries et al. [54] in a prospective cohort study comparing different numbers of non-
targeted biopsies (five, seven, or nine) to the 12-biopsy scheme (used as the reference) 
found that, in a population with a low gastric cancer risk, at least nine non-targeted 
biopsies should be taken from the cardia, lesser curvature of the corpus, angulus, and 
antrum to achieve the best diagnostic yield. Guarner et al. [55] compared protocols of 
three, five, and seven biopsies and found that the five-biopsy protocol reached 100% 
sensitivity for H. pylori, 96% for atrophy, and 95% for metaplasia and dysplasia.  
Eriksson et al. [56], in consecutive patients from a similar low risk population, took 
six biopsies (two from the antrum, two from incisura, and two from corpus). While no 
patients showed dysplasia in their incisura biopsies, these biopsies were the only ones 
to show intestinal metaplasia but, as this was seen in 3.3% of cases only, they 
concluded that routine biopsy of the incisura would provide little additional 
information. El-Zimaity et al. [57] also found that intestinal metaplasia was missed in 
more than 50% of cases, and that this was independent of the site of biopsy and that 
no set or site of biopsy specimens, including the incisura, could reliably exclude the 
presence of intestinal metaplasia. 
On the other hand, Isajevs et al. [58] assessed the relevance of the incisura biopsy and 
concluded that, if the incisura biopsy was excluded, down-staging would occur in 
18% of cases for the OLGA classification and 4% for the OLGIM, resulting in a 
30%–35% downgrading from high risk to low risk in terms of the OLGA/OLGIM 
stages. Finally, Stolte et al. [59], using the same five-biopsy protocol, concluded that 
the presence of antral mucosa at the incisura was associated with considerably more 
severe gastritis (14% atrophy and 20% intestinal metaplasia in the antrum) than the 
presence of corpus mucosa at the incisura (only 2% atrophy and 6% intestinal 
metaplasia). 
From a practical and clinical point of view, five non-targeted biopsies overall, 
comprising two from the antrum, one from the incisura, and two from the corpus, 
seems to provide the most relevant information without compromising clinical 
applicability. 
We do realize that the MAPS guidelines address more than just taking biopsies to 
assess the extent of atrophy or metaplasia. However, the emphasis of this performance 
measure lies in identifying patients at risk that should be followed up. It is obvious 
that the MAPS guidelines remain applicable independent of the proposed performance 
measures. Furthermore, depending on the prevalence of a certain disease, the attention 
that is given to the corresponding performance measure may vary geographically 
throughout Europe. For instance, follow-up and adequate diagnosis of Barrett’s 
esophagus will be more important in Western Europe, whereas intestinal metaplasia 
of the stomach may carry a higher interest in Eastern and Southern Europe. 
5 Domain: Complications 
<PerfM> 
Key performance 
measure 
Monitoring complications after therapeutic endoscopy 
Description Percentage of patients monitored for complications (adverse events) after 
therapeutic UGI endoscopy  
Domain Complications 
Category Outcome/process 
Rationale Monitoring of the incidence of complications after therapeutic endoscopy is 
important to assess the safety of procedures, to identify possible targets for 
improvement, and to allow patients to be accurately consented for 
procedures 
Construct Record therapeutic procedures including: 
– Savary dilation 
– Pneumatic dilation 
– Endoscopic resection of lesions in the esophagus, stomach, and duodenum 
– Percutaneous endoscopic gastrostomy (PEG) insertions 
– Stent placement 
– Varices band ligation 
– Endoscopic hemostasis 
– Endoscopic ablation (Barrett’s epithelium; gastric antral vascular ectasia 
[GAVE]; squamous epithelium, duodenal mucosa) 
Record the following parameters: 
– Immediate complications   
– Delayed complications: record if patient was contacted between 7 and 
14 days after the procedure to assess post-procedural complications ideally 
the patient should have been notified beforehand that this contact would be 
made 
 
Denominator: All applicable therapeutic procedures  
Numerator: Number of applicable therapeutic procedures with accurate 
registration of complications 
Exclusions: 
– Emergency procedures  
– Patients who refuse to be contacted 
 
Calculation: Proportion (%) 
Level of analysis: Service 
Frequency: Yearly on an audit sample of 100 random eligible endoscopy 
reports 
Standards Minimum standard: 95% 
Target standard: 95% 
 
Implementation of these performance measures is mainly situated on a 
service level. Because of the lack of standardized grading of complications 
into major or minor, a description of the action related to the complication 
should be given (e.g. need for transfusion or hospitalization, prolonged 
hospitalization, surgery, death, need for dilation, need for endoscopic re-
intervention), along with the time from the endoscopic procedure to onset of 
the complication 
Recording of the type of therapeutic procedure should be detailed enough to 
allow subgroup analysis 
Endoscopic reporting systems should allow the reporting of complications, 
including the absence of immediate complications, and the type of 
complication (hemorrhage, perforation, or anesthesia-related) 
Ideally the 30-day complication rate should also be calculated but this can be 
implemented at a later stage once a system to record complications 
systematically is in place 
Consensus 
agreement for 
performance measure 
91% 
PICO numbers 
(see Appendix 3) 
20–25 
Evidence grading Very low quality of evidence 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• The perforation rate following polypectomy or endoscopic mucosal resection (EMR) 
in the esophagus, stomach, or duodenum should not exceed 2%. (N9.1) Agreement: 
54% 
• The rate of clinically significant bleeding following polypectomy or EMR in the 
esophagus, stomach, or duodenum should not exceed 10% (N9.2) Agreement: 64% 
• The perforation rate following pneumatic or Savary dilation in the esophagus should 
not exceed 1%. (N9.3) Agreement: 73% 
For this domain, we specifically addressed adverse events and harms for procedures 
that are generally and frequently carried out in all endoscopic units. We focused on 
the perforation and bleeding rate after Savary or pneumatic dilation and endoscopic 
resections in the UGI tract.  
A total of 37 studies were included for complications after dilation [60–87]. They 
generally seemed to have prospectively recruited patients, but the information was 
often not very clear. Overall 3263 patients were included, of which 2202 were adults 
and 1061 children. Overall 8524 Savary and 5491 balloon dilations were performed. 
None of the studies reported cases of serious bleeding, but the majority of the studies 
did not assess this outcome. Perforations occurred in 0.98% of cases of balloon 
dilation and in 0.68% of cases of Savary dilation. Similarly, for adverse events after 
endoscopic resection, 38 papers were included [88–118]. The perforation rates were 
1.6%, 0.98%, and 1.61% in the esophagus, stomach, and duodenum, respectively, 
with bleeding rates of 4%, 6.9%, and 9.2%, respectively.  
Although the literature search yielded the highest number of included papers for these 
PICOs, including several systematic reviews, the working group could not agree on a 
predefined maximal allowance for these post-procedural adverse events. This was 
attributed to the fact that the overall quality of the evidence was graded as very low, 
being retrospective in nature and with it not always being clear if patients had been 
consecutively included in the studies. For these indications, the data were therefore 
not sufficiently adequate to decide on a threshold that would be used to audit an 
endoscopy service. Indeed, the final result would to a large extent be determined by 
the denominator, and it is therefore not clear what the incidence of adverse events 
would be in individual centers with lower numbers.  
The working group did however reach agreement on the fact that patients should be 
monitored for adverse events or harms after therapeutic interventions. This monitoring 
will generate more realistic numbers, which in turn can be used to determine a 
minimum number of procedures per service or operator for these interventions (see 
below). 
6 Domain: Procedure numbers 
<PerfM> 
Performance measure No current standard defined 
</PerfM> 
In the absence of any evidence regarding the number of procedures needed for an 
individual to be certified to perform UGI endoscopy, we were not able to set any 
minimum numbers.  
Any recommendation in terms of the minimum annual number of procedures per 
endoscopist that are required to maintain adequate levels of quality would need to be 
based on an established strong association of poor quality with a minimum threshold 
number of procedures performed per year; however, such data are unavailable. The 
working group anticipates that, with application of the present performance measures, 
information will come to light to clarify whether such a concept does apply to 
diagnostic and/or therapeutic UGI endoscopy. 
7 Domain: Patient experience 
<PerfM> 
Performance measure No current standard defined 
</PerfM> 
Patient experience and satisfaction are important outcome measures of endoscopy in 
general. The UGI working group concluded that this should be measured after any 
endoscopic procedure. In general, there is lack of evidence assessing the effect of 
certain logistic or procedural aspects on patient’s satisfaction and experience.  
The working group members concluded that this is a domain for research and, 
because it applies to all forms of endoscopy within an endoscopy service, it was 
suggested that this particular domain resides more under the service working group. 
Undoubtedly, several measures can be undertaken to improve patient’s experience. 
For instance, providing an information brochure on UGI endoscopy at least 1 day 
prior to the procedure has been shown to result in less anxiety beforehand and greater 
satisfaction after the procedure [119]. 
8 Domain: Post-Procedure 
<PerfM> 
Minor performance 
measure 
Barrett’s patient registry 
Description Percentage of patients with a confirmed diagnosis of Barrett’s esophagus that 
are entered into a registry to monitor the incidence of dysplasia  
Domain Post-procedure 
Category Process/structural 
Rationale Better follow-up of Barrett’s patients helps to identify risk factors, and helps 
with an accurate incidence of neoplasia and adherence to surveillance 
guidelines 
Construct Record all patients with a diagnosis of Barrett’s esophagus 
Cross-match with registration in a Barrett’s registry 
 
Denominator: All patients with a diagnosis of Barrett’s esophagus of at least 
1 cm circumferential extent and histologically confirmed specialized intestinal 
metaplasia  
Numerator: Patients in the denominator who are registered in a Barrett’s 
surveillance database 
Exclusions: 
– Absence of intestinal metaplasia in the biopsies 
– All patients with suspected Barrett’s esophagus that is less than C1M1 
according to the Prague classification 
– Patients older than 75 years 
– Patient’s with contraindications for biopsies 
 
Calculation: Proportion (%) 
Level of analysis: Service 
Frequency: Every 2 years for a sample of 100 eligible/applicable UGI 
endoscopies 
Standards Minimum standard: 85% 
Target standard: 85% 
 
Implementation of the measurement of this performance measure on a 
service level is challenging. Implementation of performance measures 5, 6, 
and 8 is a prerequisite. Therefore this is a regarded as a minor performance 
measure, mainly focusing on the real incidence and prevalence of the 
disease as an important research question 
Consensus 
agreement for 
performance measure 
82% 
PICO  
(see Appendix 3) 
26 
Evidence grading Very low quality of evidence 
</PerfM> 
The acceptance of this performance measure is based on agreement with the following 
statements: 
• In a Barrett's surveillance program, the incidence of dysplasia should be monitored. 
(N4.7) Agreement: 80% 
• The incidence of HGD in a Barrett's surveillance program, when diagnosed by at 
least two specialist gastrointestinal pathologists, should not be lower than 0.1% per 
year. (N4.8) Agreement: 70% 
As with the colonic adenoma detection rate that is used as a performance measure for 
colonoscopy, it would seem appropriate for UGI endoscopy to use a minimum 
detection rate for dysplasia in the surveillance of Barrett’s esophagus. From the PICO 
search, 28 studies with 49 815 patients were finally included [49,120–146]. All of the 
studies included patients with a diagnosis of Barrett’s esophagus who underwent 
regular surveillance. Of the 28 studies, 17 were retrospective or prospective studies 
assessing prevalence of LGD and HGD at baseline and the incidence of LGD and 
HGD during follow-up. The length of follow-up ranged from 1.6 to 6 years, with a 
median of 4 years. The remaining studies were cross-sectional studies that reported 
prevalence data, although often they had objectives other than the assessment of 
prevalence. These cross-sectional studies had, on average, smaller samples sizes 
ranging from 30 to 295 patients, with a median of 80 patients included. Sample sizes 
of the cohort studies ranged from 121 to 42 207 included patients, with a median of 
277 patients.  
Although the quality of the evidence was rated as moderate, because of inconsistency 
in the data, no agreement was achieved in the Delphi process on a specific cut-off for 
the detection of dysplasia. Indeed, the prevalence of LGD ranged from 0.6% to 33.3% 
in the cross-sectional studies and from 0 to 37.2% in the cohort studies, with the 
prevalence of HGD ranging from 0 to 14.6% and 0 to 23.9%, respectively. The 
incidence of LGD and HGD ranged from 2% to 34.5% and from 0% to 5.8%, with 
median values of 14.7% and 2%, respectively. 
Although no agreement was obtained on the cut-off for dysplasia detection, the 
working group members agreed on the fact that the incidence of dysplasia in a 
Barrett’s esophagus surveillance program should be monitored in order to obtain more 
consistent and accurate epidemiological data. When these data become available, a 
more realistic cut-off value may be determined, taking into account geographical 
differences and other risk factors of progression. 
General conclusions, research priorities, and future prospects 
This paper describes the first performance measures generated by evidence-based 
consensus that can be used for UGI endoscopy. We used a systematic and 
scientifically sound methodology to substantiate the proposed measures with available 
evidence where possible. As this is a largely unexplored field, most of the generated 
evidence is, as expected, graded as low quality. This in itself generates an important 
research priority, which is merely to measure the proposed performance measures and 
to evaluate whether they do in fact influence health outcome.  
The working group identified several additional research priorities. These are listed in 
Table 3 and will be addressed in an additional manuscript from the ESGE research 
committee. 
The first step now is to implement these new performance measures into endoscopy 
practice over Europe. This is the only way forward that can evaluate the actual value 
of the performance measures and allow their adaptation in future. The working group 
members emphasize that all performance measures were perceived as important but, 
in order to facilitate their implementation, we made a distinction between key 
performance measures and minor performance measures. Although this distinction is 
somewhat arbitrary, attention was paid especially to patient safety, patient service 
(increasing diagnostic yield), and the feasibility of implementation. Indeed, some of 
the performance measures may be more difficult than others to implement or, because 
of geographical differences in disease prevalence, may be less relevant in certain 
centers. 
The implementation of performance measures is important to identify services and 
individual endoscopists with lower levels of performance. We encourage individual 
endoscopists, as well as heads of endoscopy units, to start the implementation of these 
performance measures without delay. At a unit level, this may well mean investing in 
hardware to accommodate a more efficient auditing process.  
Through individual feedback, measures can be taken to improve quality to rise above 
the proposed minimum thresholds. This should not be regarded as a “big brother” 
strategy with the goal of penalizing specific endoscopists, but rather as a tool to 
improve the quality of endoscopy in general, improve patient outcomes, and provide 
training and assistance where needed.  
A second barrier may be the financial repercussions of implementing a quality control 
system. We want to encourage hospital management to support the implementation of 
these performance measures in their endoscopy services. We think that in an era 
where general hospital accreditation is becoming more and more important, hospital 
administrations will be more inclined to support such actions. Moreover, we owe it to 
our patients to overcome individual or financial barriers to ensure that endoscopy 
services are of the highest quality and to set research priorities to gather data that will 
inform the next generation of performance measures. 
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Fig. 1 The domains and performance measures chosen by the working 
group (MAPS, management of precancerous conditions and lesions in the 
stomach; SCC, squamous cell carcinoma). 
  
Table e1 Confidence intervals (CI) with varying thresholds and sample 
sizes. 
Threshold  P 1-P n SE Lower 
95% CI 
Higher 
95% CI 
0.85 0.85 0.15 100 0.03571 0.78 0.92 
0.85 0.85 0.15 200 0.02525 0.80 0.90 
0.85 0.85 0.15 250 0.02258 0.81 0.89 
0.85 0.85 0.15 300 0.02062 0.81 0.89 
0.85 0.85 0.15 400 0.01785 0.82 0.88 
0.85 0.85 0.15 500 0.01597 0.82 0.88 
0.85 0.85 0.15 1000 0.01129 0.83 0.87 
0.90 0.9 0.1 100 0.03000 0.84 0.96 
0.90 0.9 0.1 200 0.02121 0.86 0.94 
0.90 0.9 0.1 250 0.01897 0.86 0.94 
0.90 0.9 0.1 300 0.01732 0.87 0.93 
0.90 0.9 0.1 400 0.01500 0.87 0.93 
0.90 0.9 0.1 500 0.01342 0.87 0.93 
0.90 0.9 0.1 1000 0.00949 0.88 0.92 
0.95 0.95 0.05 100 0.02179 0.91 0.99 
0.95 0.95 0.05 200 0.01541 0.92 0.98 
0.95 0.95 0.05 250 0.01378 0.92 0.98 
0.95 0.95 0.05 300 0.01258 0.93 0.97 
0.95 0.95 0.05 400 0.01090 0.93 0.97 
0.95 0.95 0.05 500 0.00975 0.93 0.97 
0.95 0.95 0.05 1000 0.00689 0.94 0.96 
SE, standard error 
  
Table 2 Description of the different performance measures. 
Key performance measures Minor performance measures 
Fasting instructions prior to UGI 
endoscopy 
Minimum 7-minute procedure time for first 
diagnostic UGI endoscopy and follow-up 
of gastric intestinal metaplasia 
Documentation of procedure duration Minimum 1-minute inspection time per cm 
circumferential Barrett’s epithelium 
Accurate photodocumentation of 
anatomical landmarks and abnormal 
findings 
Use of Lugol chromoendoscopy in 
patients with a curatively treated ENT or 
lung cancer to exclude a second primary 
esophageal cancer 
Accurate application of standardized 
disease-related terminology 
Application of validated biopsy protocol to 
detect gastric intestinal metaplasia (MAPS 
guidelines) 
Application of Seattle protocol in Barrett’s 
surveillance 
Prospective registration of Barrett’s 
patients 
Accurate registration of complications 
after therapeutic UGI endoscopy 
 
UGI, upper gastrointestinal; ENT, ear, nose, and throat; MAPS, management 
of patients with precancerous conditions and lesions of the stomach. 
  
Table 3 Research priorities identified by the working group. 
What is the percentage detection of dysplasia in a Barrett’s surveillance 
program in a general endoscopy practice? 
What is the percentage of intestinal metaplasia in the stomach throughout 
Europe in a general endoscopy practice? 
Could visualization of the papilla of Vater be used as a measure for a 
complete and high quality endoscopy?  
Does the percentage of endoscopies where the papilla is visualized correlate 
with a higher general diagnostic yield during UGI endoscopy? 
What is the relationship between inspection time during UGI endoscopy and 
diagnostic yield? 
The role of endoscopy in redefining diseases of the UGI tract 
Endoscopy with or without biopsies  
    Do biopsies alter the management of patients with Barrett’s esophagus or 
eosinophilic esophagitis? 
What is the role of advanced imaging in a general endoscopy practice for 
dysplasia detection in: 
    Barrett’s esophagus 
    Squamous cancer detection in high risk patients 
    Intestinal metaplasia in the stomach? 
Can automated image analysis remove the need for biopsies and guide the 
management of patients with: 
    Barrett’s esophagus 
    Intestinal metaplasia of the stomach 
    Celiac disease? 
What is the role of teaching modules in training endoscopists in image 
interpretation and lesion recognition? 
UGI, upper gastrointestinal. 
  
Appendix e1 Excel file for Delphi voting process.  
 
Appendix e2 
The number of procedures that need to be used when auditing a particular 
performance measure to obtain an accurate estimate for performance is shown in  
  
Table e1. For performance measures with a threshold of 85%, the number is 250; for 
performance measures with a threshold of 90% or 95%, the number is 300. 
Furthermore, as indicated in the table, the additional benefit in terms of narrowing of 
the 95% confidence interval (CI) is negligible for bigger sample sizes. The most 
significant gain in accuracy is achieved by increasing the sample from 100 to 200.  
  
Appendix 3 The list of specific PICOs that were used for the final performance 
measures. 
 Patients Intervention Comparison Outcome 
1 Patients undergoing 
UGI endoscopy 
Time spent in the 
stomach 
None Higher overall 
diagnostic yield in 
the stomach 
2 Patients undergoing 
UGI endoscopy 
Time spent in the 
stomach 
None Higher overall 
diagnostic yield in 
the stomach 
3 Patients undergoing 
UGI endoscopy 
Visualizing a 
specific 
structure/disease 
Not visualizing a 
specific 
structure/disease 
Higher overall 
diagnostic yield in 
the stomach 
4 Patients undergoing 
UGI endoscopy 
Picture of 
anatomical 
landmarks 
No picture 
documentation 
Higher overall 
diagnostic yield 
5 Patients undergoing 
UGI endoscopy 
Picture of abnormal 
findings 
No picture 
documentation 
Higher overall 
diagnostic yield 
6 Patients with reflux 
undergoing UGI 
endoscopy 
Endoscopy report 
documenting Z line 
morphology 
Endoscopy report 
not documenting Z 
line morphology 
Higher diagnostic 
accuracy to 
diagnose reflux 
esophagitis 
7 Patients with reflux 
undergoing UGI 
endoscopy 
Documentation of 
Los Angeles 
classification 
No documentation 
of Los Angeles 
classification 
Diagnosis of 
erosive esophagitis 
8 Patients undergoing 
UGI endoscopy 
Standardized 
reporting system 
No standardized 
reporting system 
Higher overall 
diagnostic yield 
9 Patients undergoing 
Barrett's 
surveillance 
endoscopy 
Classification as per 
Prague criteria 
No mention of 
Prague criteria 
Accurate diagnosis 
of Barrett's 
10 Patients with 
Barrett's and visible 
lesions 
Reporting on visible 
lesions according to 
the Paris 
classification 
No mention of 
visible lesion 
morphology and 
location 
Accurate 
documentation of 
visible lesions in 
Barrett's / Better 
communication 
among physicians 
11 Patients with 
Barrett's and visible 
lesions 
Reporting on visible 
lesions according to 
the Paris 
classification 
No mention of 
visible lesion 
morphology and 
location 
Higher diagnostic 
yield for Barrett’s 
dysplasia. 
12 Patients with a 
history of squamous 
cell ear, nose and 
throat tumors, 
treated with curative 
intent, referred for 
screening 
chromoendoscopy 
for squamous 
dysplasia or cancer 
with a visible lesion 
Systematic use of 
standardized 
reporting of lesions 
found according to 
the Paris 
classification 
No systematic 
report 
Need to repeat the 
endoscopy for 
accurate diagnosis 
13 Patients referred for 
gastroscopy 
Systematic 
standardized 
reporting of visible 
lesions according to 
Paris classification 
No systematic 
standardized 
reporting of visible 
lesions 
Increased detection 
of intestinal 
metaplasia, 
dysplasia and 
gastric cancer 
14 Barrett's patients 
undergoing 
surveillance 
endoscopy 
Measuring the 
Barrett's inspection 
time 
No measurement of 
inspection time 
Increased dysplasia 
detection 
15 Patients with a 
history of squamous 
cell ear, nose and 
throat tumors, 
treated with curative 
intent, referred for 
screening for 
squamous 
dysplasia or cancer 
Screen by 
chromoendoscopy 
with Lugol 
No screening with 
chromoendoscopy 
Increased detection 
of squamous 
dysplasia and 
cancer in the 
esophagus 
16 Barrett's patients 
undergoing 
surveillance 
endoscopy 
Systematic biopsy 
as per Seattle 
protocol 
Non systematic 
biopsy protocol 
followed 
Early detection of 
neoplasia 
17 Barrett's patients 
undergoing 
surveillance 
endoscopy 
Systematic biopsy 
as per Seattle 
protocol 
Non-systematic 
biopsy protocol 
followed 
Decreased mortality 
from 
adenocarcinoma of 
the esophagus 
18 Barrett's patients 
undergoing 
surveillance 
endoscopy 
Systematic biopsy 
as per Seattle 
protocol 
Non-systematic 
biopsy protocol 
followed 
Detection of 
dysplasia or cancer 
at an early stage 
(could be searched 
as “need for 
esophagectomy” or 
treatment by 
“endoscopic 
resection” or 
“radiofrequency 
ablation”) 
19 Patients referred for 
gastroscopy 
Systematic biopsies 
of antrum, corpus, 
and angulus 
No systematic 
biopsies 
Increased detection 
of intestinal 
metaplasia, 
dysplasia, and 
gastric cancer 
20 Patients with a 
benign or malignant 
stricture in the 
esophagus 
(achalasia 
excluded) 
Savary dilation None Percentage of 
patients with 
perforation 
21 Patients with a 
benign or malignant 
stricture in the 
esophagus 
(achalasia 
excluded) 
Savary dilation None Percentage of 
patients with 
bleeding 
22 Patients with a 
benign or malignant 
stricture in the 
esophagus 
(achalasia 
excluded) 
Pneumatic dilation None Percentage of 
patients with 
perforation 
23 Patients with a 
benign or malignant 
stricture in the 
esophagus 
(achalasia 
excluded) 
Pneumatic dilation None Percentage of 
patients with 
bleeding 
24 Patients with a 
benign or malignant 
lesion in the 
esophagus, 
stomach, or 
duodenum (SCC, 
HGD, LGD, 
adenoma, 
papilloma, stomach 
cancer, 
adenocarcinoma) 
Endoscopic 
resection (EMR or 
polypectomy in 
esophagus, 
stomach or 
duodenum) 
None Percentage of 
patients with 
perforation 
25 Patients with a 
benign or malignant 
lesion in the 
esophagus, 
stomach, or 
duodenum (SCC, 
HGD, LGD, 
adenoma, 
papilloma, stomach 
cancer, 
adenocarcinoma)  
Endoscopic 
resection (EMR or 
polypectomy in 
esophagus, 
stomach, or 
duodenum) 
None Percentage of 
patients with 
bleeding 
26 Patients undergoing 
Barrett's 
surveillance 
endoscopy 
UGI endoscopy with 
dysplasia in biopsy 
UGI endoscopy 
without dysplasia in 
biopsy 
Percentage of 
patients diagnosed 
with HGD 
UGI, upper gastrointestinal endoscopy; SCC, squamous cell cancer; HGD, 
high grade dysplasia; LGD, low grade dysplasia; EMR, endoscopic mucosal 
resection.  
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